RxDoctor Payments DataLook up a doctor →

York Moy, MD

Urology · Middlebury, CTNPI 1083678247

Payments from drug & device makers

$129,484in general payments, 2019–2025

Across 679 payments — averaging $190.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$106K
  • GSK$8K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$1K
  • Antares Pharma, Inc.$863
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$14,86294%
  • Education$1,0156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,484 in reported general payments places this provider in the 95th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$395,040
Medicare patients
926
Services billed
7,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide27$403,469
OrgovyxRelugolix108$290,651
GemtesaVibegron204$245,878
NubeqaDarolutamide15$206,098
MyrbetriqMirabegron156$165,723
XyostedTestosterone Enanthate48$49,446
Mirabegron ErMirabegron54$44,208
Potassium Citrate ErPotassium Citrate245$15,376
Silodosin160$14,469
Alfuzosin Hcl ErAlfuzosin Hcl652$12,809
Methenamine Hippurate217$12,614
Tamsulosin Hcl789$10,933
Tadalafil52$10,440
Testosterone Cypionate122$9,799
Oxybutynin Chloride ErOxybutynin Chloride283$7,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,027$536,529312 claims
Johnson & JohnsonErleada$1,147$403,46927 claims
BayerNubeqa$261$206,09815 claims
Astellas Pharma US IncMyrbetriq$1,098$165,723156 claims
Antares Pharma, Inc.Xyosted$863$49,44648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 urology providers in Connecticut.

Other urology in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →